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Antiretroviral treatment simplification with darunavir/ritonavir or lopinavir/ritonavir monotherapy maintains sustained
HIV viremia suppression in clinical trials. However, data about the efficacy of this strategy in routine clinical practice is still
limited, and no direct comparison between darunavir/ritonavir and lopinavir/ritonavir has been performed to date. We
retrospectively studied all HIV-1-infected subjects who initiated monotherapy with darunavir/ritonavir or lopinavir/ritonavir
while having plasma VLB50 c/mL, and had at least 1 subsequent follow-up visit in our clinic. When two consecutive
PI-monotherapy regimens were used, each regimen was considered separately. The primary endpoint was the percentage of
patients who maintained virological suppression (HIV-1 VL B50 c/mL) through follow-up. Virological failure was defined as at
least two consecutive HIV-1 VL  50 c/mL. We also evaluated other reasons for treatment discontinuation. Analyses were
performed considering all regimens (full dataset analysis) either as ‘‘on treatment’’ or as ‘‘treatment switch equals failure’’. Five
hundred and seventy-three PI-monotherapy regimens corresponding to 520 subjects were included, 262 with darunavir/
ritonavir and 311 with lopinavir/ritonavir. Medians (IQR) follow-up were 50 (26.3107.6) and 85.6 (36.9179.1) weeks for
subjects on darunavir/ritonavir and lopinavir/ritonavir, respectively (pB0.001). Overall, 67 (11.7%) subjects experienced
virological failure, 23 (8.7%) were on darunavir/ritonavir and 42 (13.5%) were on lopinavir/ritonavir (p0.796). Two hundred
and three (77.5%) patients on darunavir/ritonavir and 154 (49.5%) on lopinavir/ritonavir maintained virological suppression in
the ‘‘treatment switch equals failure’’ (p0.002). Other reasons for treatment discontinuation were gastrointestinal toxicity and
dyslipidemia in 7.2% and 5.9% of cases, respectively. Gastrointestinal toxicities and dyslipidemia leading to treatment
discontinuation were more frequent in patients on lopinavir/ritonavir (10.6% and 10.3%, respectively) than in patients on
darunavir/ritonavir (3.1% and 0.8%, respectively). Monotherapy with darunavir/ritonavir or lopinavir/ritonavir as simplification
strategy appears to be effective and safe in subjects with virological suppression in clinical practice.Virological efficacy seems to
be similar between regimens. However, rates of discontinuation due to toxicities were higher in subjects on lopinavir/ritonavir
than darunavir/ritonavir.
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